Physician profile
Jonathan L Cleaver
NPI 1033431903
$483,262.89
in general payments reported to CMS, 2019-2025
41 companies · $53K in 2025
The $53K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95K · 2020: $44K · 2021: $49K · 2022: $81K · 2023: $54K · 2024: $106K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $168K · Travel and Lodging: $28K · Food and Beverage: $11K · Consulting Fee: $6,076 · Education: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $168,150.00 |
| Travel and Lodging | $27,875.23 |
| Food and Beverage | $10,598.77 |
| Consulting Fee | $6,076.00 |
| Education | $427.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316,200.76 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Amgen INC. | $84,057.05 | 2019-2025 | Otezla, Otezla |
| Celgene Corporation | $39,979.28 | 2019 | |
| Lilly USA, LLC | $25,493.82 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $7,944.17 | 2022-2025 | Sotyktu |
| Ucb, INC. | $2,321.05 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $945.78 | 2019-2025 | Ilumya, Blu-U, Winlevi |
| Janssen Biotech, INC. | $924.22 | 2020-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $823.50 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $657.51 | 2019-2025 | |
| Genzyme Corporation | $386.15 | 2019-2025 | |
| Pfizer INC. | $385.26 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $357.56 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $331.99 | 2022-2025 | |
| Galderma Laboratories, L.P. | $290.17 | 2021-2024 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cleaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.